BNTX — BioNTech SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1776985 ·
Last close
$89.33
Market Cap
$22.59B
52W High
$107.14
52W Low
$84.96
ADV30
894,107
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 118,100,000 | 46,700,000 | -677,500,000 | -531,900,000 | 21,074,100,000 | 9,939,400,000 | 2,376,300,000 |
| Dec 2025 | 907,400,000 | 574,100,000 | -280,500,000 | -305,000,000 | 21,988,600,000 | 7,675,400,000 | 2,764,400,000 |
| Sep 2025 | 1,518,900,000 | 1,370,600,000 | 653,900,000 | -28,700,000 | 21,341,100,000 | 10,092,900,000 | 2,863,800,000 |
| Jun 2025 | 260,800,000 | 184,400,000 | -478,500,000 | -386,600,000 | 21,637,600,000 | 10,269,500,000 | 3,132,500,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$815,700,000
Investing CF
$-1,064,700,000
Financing CF
$-12,700,000
CapEx
$-209,800,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-5.07
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$17,430,000,000
Inventory
$103,800,000
Receivables
$612,200,000
ST Investments
$4,699,800,000
EBIT TTM
$-978,700,000
Pretax Income TTM
$-1,173,500,000
Interest Exp TTM
$14,600,000
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,805,199,872
EBITDA
$-1,191,299,968
Free Cash Flow
$-428,112,512
Enterprise Value
$9,876,724,736
Total Cash
$13,706,600,448
Total Debt
$302,800,000
Shares Out
252,884,261
Trailing EPS
$-5.78
Book Value
$84.37
ROE
-6.7%
ROA
-4.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,869,900,000 | -640,700,000 | -1,136,100,000 | 21,988,600,000 | 2,764,400,000 | — | 456,000,000 |
| Dec 2024 | 2,751,100,000 | -709,400,000 | -665,300,000 | 22,529,700,000 | 3,118,600,000 | — | 207,700,000 |
| Dec 2023 | 3,819,000,000 | 875,600,000 | 930,300,000 | 23,006,300,000 | 2,760,400,000 | — | 5,371,400,000 |
| Dec 2022 | 17,310,600,000 | 12,303,800,000 | 9,434,400,000 | 23,279,100,000 | 3,223,500,000 | — | 13,577,400,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.94
Max Pain — expiry 2026-08-21
max pain strike: $90.00 · spot: $89.33 · call oi: 4,535 · put oi: 3,588
Expected Move to 2026-08-21:
±$9.00
(10.08%) —
implied range
$80.33 –
$98.33
· ATM straddle on $90.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRNA | Moderna, Inc. | $21.45B | $54.07 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $17.67B | $175.77 | — |
| BIIB | BIOGEN INC. | $29.85B | $202.19 | — |
| EXEL | EXELIXIS, INC. | $13.92B | $55.37 | — |
| RVMD | Revolution Medicines, Inc. | $40.23B | $189.23 | — |
News headlines (Yahoo Finance, 1h cache)
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
2026-07-24 15:06 · Yahoo
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
2026-07-21 10:45 · Yahoo
Is BioNTech (BNTX) Undervalued As It Exits German Manufacturing Sites?
2026-07-10 21:10 · Yahoo
BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump
2026-07-10 12:15 · Yahoo
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
2026-07-08 15:11 · Yahoo
Former Pfizer Building Is Crumbling—Just as the Stock Has
2026-07-07 19:22 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
2026-07-06 15:21 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
2026-07-02 15:13 · Yahoo
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
2026-06-18 14:34 · Yahoo
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
2026-06-18 12:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.